logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Journal Article
|Research

Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India

Burza S, Sinha PK, Mahajan R, Gonzalez Sanz M, Lima MA, Mitra G, Verma N, Das P
Download

Similar Content
Loading...
Loading...
Loading...
Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India | Journal Article / Research | MSF Science Portal
Abstract
The skin disorder Post Kala-Azar Dermal Leishmaniasis (PKDL) occurs in up to 10% of patients treated for visceral leishmaniasis (VL) in India. The pathogenesis of PKDL is not yet fully understood. Cases have been reported in India following therapy with most available treatments, but rarely in those treated with liposomal amphotericin B (Ambisome). Between July 2007 and August 2012 with the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) supported a VL treatment programme in Bihar, India-an area highly endemic for Leishmania donovani-in which 8749 patients received 20 mg/kg intravenous Ambisome as first-line treatment. This study describes the characteristics of patients who returned to the MSF supported treatment programme with PKDL.

Countries

India

Subject Area

neglected tropical diseaseskala azar

Languages

English
DOI
10.1371/journal.pntd.0002611
Published Date
02 Jan 2014
PubMed ID
24392171
Journal
PLOS Neglected Tropical Diseases
Volume | Issue | Pages
Volume 8, Issue 1, Pages e2611
Issue Date
2014-01-02
Dimensions Badge